In vivo CRISPR screens identify Mga as an immunotherapy target in triple-negative breast cancer
Xu Feng,Chang Yang,Yuanjian Huang,Dan Su,Chao Wang,Lori Lyn Wilson,Ling Yin,Mengfan Tang,Siting Li,Zhen Chen,Dandan Zhu,Shimin Wang,Shengzhe Zhang,Jie Zhang,Huimin Zhang,Litong Nie,Min Huang,Jae-Il Park,Traver Hart,Dadi Jiang,Kuirong Jiang,Junjie Chen
DOI: https://doi.org/10.1073/pnas.2406325121
2024-09-24
Abstract:Immune evasion is not only critical for tumor initiation and progression, but also determines the efficacy of immunotherapies. Through iterative in vivo CRISPR screens with seven syngeneic tumor models, we identified core and context-dependent immune evasion pathways across cancer types. This valuable high-confidence dataset is available for the further understanding of tumor intrinsic immunomodulators, which may lead to the discovery of effective anticancer therapeutic targets. With a focus on triple-negative breast cancer (TNBC), we found that Mga knock-out significantly enhances antitumor immunity and inhibits tumor growth. Transcriptomics and single-cell RNA sequencing analyses revealed that Mga influences various immune-related pathways in the tumor microenvironment. Our findings suggest that Mga may play a role in modulating the tumor immune landscape, though the precise mechanisms require further investigation. Interestingly, we observed that low MGA expression in breast cancer patients correlates with a favorable prognosis, particularly in those with active interferon-γ signaling. These observations provide insights into tumor immune escape mechanisms and suggest that further exploration of MGA's function could potentially lead to effective therapeutic strategies in TNBC.